Ariad Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$88.5M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Ariad Pharmaceuticals's total funding is $88.5M.

Employee Data

  • Ariad Pharmaceuticals has 210 Employees.(?)
  • Ariad Pharmaceuticals currently has 1 job openings.

ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company's development pipeline includes: a drug candidate that controls cell proliferation and nutrient uptake by tumors to treat cancer; a bone-targeted drug candidate to treat the complications of cancer that has spread to bone; a regulated protein therapy product candidate to treat anemia in which the production of erythropoietin is controlled in vivo using an orally administered drug; a T cell immunotherapy product candidate in which a non-immunosuppressive drug may be used to treat graft-vs-host disease following donor bone marrow transplantation - a therapy for cancer and other immune and blood diseases; and dual-action drug candidates that block bone resorption and stimulate bone formation to treat osteoporosis. ARIAD also has an exclusive license to pioneering technology related to the discovery, development, and use of drugs that modulate the NF-(kappa)B pathway, which has been implicated in many major diseases